Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Packet of Tramadol tablets

Although tramadol is increasingly used to manage non-cancer pain, few safety studies have compared it with other opioids in actual practice conditions. A new study, published in JAMA, provides evidence that tramadol is associated with an increased risk of mortality and adverse clinical outcomes, and highlights the need for future research on its safety.

The population-based cohort study on 368,960 participants reviewed a new dispensation of tramadol, compared with codeine. The international research team prespecified eight outcomes that had been previously correlated to the opioid use including: all-cause mortality, cardiovascular events, fractures, constipation, delirium, falls, opioid abuse/dependence, and sleep disorders within one-year after the first dispensation. Codeine was used as the comparator as both tramadol and codeine are weak opioids, prescribed for addressing similar pain and illness.

Junqing Xie, DPhil student and lead author said: "Compared with codeine, our study showed that tramadol was associated with an increased risk of mortality, cardiovascular events, and fractures, but we saw no increased risk for the other measures we explored. The results for mortality are quite surprising because tramadol is accepted as being a safer opioid. The findings should be interpreted cautiously given the potential for residual confounding."

The findings were also consistent when applied over a range of subgroups, which means these effects could be seen in different age groups, and across different pain indications in adults.

The use of opioids to treat severe cancer and non-cancer pain has led to a decades-long epidemic in the United States where death rates and adverse effects on public health from opioid use are significant. Recently, more and more data show that the opioids have been increasingly prescribed for a variety of painful conditions in other countries like Canada, Australia, Europe and the UK. "The increased use of tramadol is a concern because if it's considered a safe drug, it might be prescribed more casually. We think while more data is urgently needed for the tramadol safety profile, clinicians should err on the side of caution when considering this treatment," concluded Carlen Reyes, a doctor and the corresponding author for this study.

Similar stories

Matthew Costa elected Fellow of Academy of Medical Sciences

Matthew Costa, Professor of Orthopaedic Trauma Surgery at NDORMS, has been elected a Fellow of the Academy of Medical Sciences.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Nurses' Day 2022

Today marks Nurses' Day 2022. This year's theme is #BestofNursing, so we chatted to some of our amazing Research Nurses about what the Best of Nursing means to them.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.